student +49 (0)511 532 8954 Czichon.Laurien @ mh-hannover.de David Puertollano Martin PhD student +49(0)511 532 8954 PuertollanoMartin.David @ mh-hannover.de Theresa Niemöller PhD student +49(0)511 532 8902
RG Martin Research Group Martin The RG Martin is interested not only in developing individualized cell and gene therapies for cardiac and pulmonary diseases, but also in investigating disease mechanisms [...] ecific iPS cell lines Table of different patient-or disease-specific iPS cell lines in RG Martin In the Martin group, iPS cells have so far been produced from cells from mice and humans , but also from [...] e methods to animal experiments. Therefore, the following research areas are addressed in the RG Martin: 1. Reprogramming of somatic cells into clinically applicable induced pluripotent stem cells (iPSCs)
ETPN announces Prof. Martin as new vice chair ot the Working Group Regenerative Medicine In May 2011, Prof. Martin was elected as vice chair to lead together with Dr. Elisa Figallo (chair; project manager
Artificial Organs (LEBAO) at the Hannover Medical School (MHH) and LEBAO director Professor Dr. Ulrich Martin, now want to develop a new therapy in which damaged tissue areas can be repaired with the help of [...] and improve organ function in animal models as part of the iCARE project coordinated by Professor Martin. In the new research project HEAL, the strategies for producing and administering the iPS cardiomyocyte [...] the iPS cells that can be activated if the applied cells degenerate in the body," says Professor Martin. "In the end, we want to produce safe cell products that can also be produced on a large scale in
n , please contact Professor Dr Corinna Trebst, trebst.corinna@mh-hannover.de or Dr Martin Hümmert, huemmert.martin@mh-hannover.de , telephone (0511) 532-2390. Further information about the NEMOS network [...] decisions and for increasing the quality of care for our patients," says initiator and first author Dr Martin Hümmert, explaining the background of the study. Until now, there was insufficient data on NMOSD [...] "As the severity of the disease increases, the socio-economic costs rise dramatically," notes Dr Martin Hümmert. "At the same time, the quality of life of those affected decreases." On average, patients
vectors for gene therapy of inner ear disorders by directed evolution Hanna L. Redeker, nee Martin GERMANY Martin.Hanna @ mh-hannover.de Supervisor: Prof. Dr. Arndt Vogel / Dr. Anna Saborowski (Gastroenterology [...] exam June 2023 Nurul Khalida Ibrahim MALAYSIA Ibrahim.Nurul @ mh-hannover.de Supervisors: Prof. Dr. Martin Stanulla / Laura Hinze (Pediatric Hematology & Oncology) Project: Deciphering the molecular regulation [...] Final exam November 2024 Ömer Kocdölü GERMANY Kocdoelue.Oemer @ mh-hannover.de Supervisor: PD Dr. Martin Fischer/ Prof. Dr. Christian Wahl-Schott (Neurophysiology) Project: Functional characterization of
Sabine Schicht Phone: +49 511 532-7868 Email: Dr. Sabine Schicht Dr. med. Martin Wetzke Phone: +49 511 532 3204 Email: Martin Wetzke Profile Scientific staff Anika Habener Phone: +49 511 532-6066 Email:
and Martin Engelhard. (2002) Probing the Proton Channel and the Retinal Binding Site of Natronobacterium pharaonis Sensory Rhodopsin II. Biophysical Journal 82:2156–2164. Igor Chizhov and Martin Engelhard [...] Schmies, Igor Chizhov, Martin Engelhard. (2000) Functional expression of His-tagged sensory rhodopsin I in Escherichia coli. FEBS Letters 466:67-69 Ansgar A. Wegener, Igor Chizhov, Martin Engelhard and Hei [...] motor. The FASEB Journal. Vol.29, No.1 , Pages: 81-94 Marc Dittmann, Ralf Seidel, Igor Chizhov and Martin Engelhard (2014) Total chemical synthesis of a membrane protein domain analogue containing two t
tissue in vitro, European Heart Journal 2013 For the first time, the team of Ina Gruh and Ulrich Martin was able to demonstrate that contracting heart muscle tissue (bioartificial cardiac tissue, BCT) [...] Azizian, A., Wagner, S., Maier, L. S., Krause, A., Drager, G., Ochs, M., Haverich, A., Gruh, I.#, and Martin, U.#. 2013. Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial
cells for the therapy of SD. In parallel, together with a project of the research group from Prof. Martin and funded by the “Mukoviszidose e.V.”, technologies are currently being developed to correct the [...] patient-derived iPSCs prior to differentiation into the desired respiratory cell type (see also RG Martin ). In our group, we have already established efficient protocols for the differentiation of murine [...] human iPS reporter cell lines which are generated using TALEN-based homologues recombination ( RG Martin ). Following the above priorities, the current state of research forms the basis for innovative,